公开(公告)号：US11129810B2

公开(公告)日：2021-09-28

申请号：US16793922

申请日：2020-02-18

申请人： MEREO BIOPHARMA 1 LIMITED

发明人： Colin Orford ,  Cyril Clarke ,  Colm Farrell ,  Jacqueline Parkin ,  Stefan De Buck

IPC分类号： A61K31/415 ,  A61P11/00 ,  A61K9/00

摘要： This invention relates to a novel dosage regimen for administration of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable derivative thereof, namely in the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD).

公开(公告)号：US11234967B2

公开(公告)日：2022-02-01

申请号：US15733213

申请日：2018-12-11

申请人： MEREO BIOPHARMA 1 LIMITED

发明人： Jacqueline Parkin ,  Alastair McKinnon

IPC分类号： A61K31/415

摘要： The invention relates to dosage regimens for administering pharmaceutical compositions comprising 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide for the treatment of a human patient suffering from COPD, or suffering from an acute exacerbation of COPD, or at risk of developing an acute exacerbation of COPD, or to prevent a reoccurrence of an acute exacerbation of COPD, or to prevent a treatment failure of an acute exacerbation of COPD, and to methods of prevention or reduction in the rate of acute exacerbations of COPD in a human patient.

公开(公告)号：US11701341B2

公开(公告)日：2023-07-18

申请号：US15733212

申请日：2018-12-11

申请人： MEREO BIOPHARMA 1 LIMITED

发明人： Alastair MacKinnon ,  Jacqueline Parkin

IPC分类号： A61K31/415 ,  A61P11/00 ,  A61K9/00

CPC分类号： A61K31/415 ,  A61P11/00 ,  A61K9/0053

摘要： The invention relates to pharmaceutical compositions comprising 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide for use in the treatment of acute exacerbations of chronic obstructive pulmonary disease in human patients having

公开(公告)号：US10603306B2

公开(公告)日：2020-03-31

申请号：US16082765

申请日：2016-03-08

申请人： MEREO BIOPHARMA 1 LIMITED

发明人： Colin Orford ,  Cyril Clarke ,  Colm Farrell ,  Jacqueline Parkin ,  Stefan De Buck

IPC分类号： A61K31/415 ,  A61P11/00 ,  A61K9/00

摘要： This invention relates to a novel dosage regimen for administration of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable derivative thereof, namely in the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD).